Federal Register / Vol. 69, No. 240 / Wednesday, December 15, 2004 / Notices 75075

II. Electronic Access

Persons with access to the Internet 

may obtain the documents at http://

www.fda.gov/cdrh/pmapage.html.

Dated: December 3, 2004.

Linda S. Kahan,

Deputy Director, Center for Devices and 

Radiological Health.

[FR Doc. 04–27387 Filed 12–14–04; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Advisory Committee on Heritable 

Disorders and Genetic Diseases in 

Newborns and Children; Notice of 

Meeting 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Public Law 92–463), notice is hereby 

given of the following meeting:

Name: Advisory Committee on Heritable 

Disorders and Genetic Diseases in Newborns 

and Children (ACHDGDNC). 

Dates and Times: January 13, 2005, 9 a.m. 

to 5 p.m. January 14, 2005, 9 a.m. to 5 p.m. 

Place: Ronald Reagan Building and 

International Trade Center, 1300 

Pennsylvania Avenue, NW., Washington, DC 

20004. 

Status: The meeting will be open to the 

public with attendance limited to space 

availability. 

Purpose: The Advisory Committee 

provides advice and recommendations 

concerning the grants and projects authorized 

under the Heritable Disorders Program and 

technical information to develop policies and 

priorities for this program that will enhance 

the ability of State and local health agencies 

to provide for newborn and child screening, 

counseling and health care services for 

newborns and children having or at risk for 

heritable disorders. Specifically, the 

Committee shall advise and guide the 

Secretary regarding the most appropriate 

application of universal newborn screening 

tests, technologies, policies, guidelines and 

programs for effectively reducing morbidity 

and mortality in newborns and children 

having or at risk for heritable disorders. 

Agenda: The first day will be devoted to 

presentations on and a discussion of the 

status of the report from the American 

College of Medical Genetics; an update of the 

current status of state specific issues; 

presentations on the Rare Disease Centers of 

Excellence funded by the National Institutes 

of Health and the Regional Genetics; and 

Newborn Screening Collaboratives funded by 

the Health Resources and Services 

Administration. The presentations will be 

followed on the first and second day with 

more detailed discussions aimed at 

formulating the ACHDGDNC issues agenda. 

Proposed agenda items are subject to 

change. 

Time will be provided each day for public 

comment. Individuals who wish to provide 

public comment or who plan to attend the 

meeting and need special assistance, such as 

sign language interpretation or other 

reasonable accommodations, should notify 

the ACHDGDNC Executive Secretary, 

Michele A. Lloyd-Puryear, M.D., Ph.D. 

(contact information provided below). 

Contact Person: Anyone interested in 

obtaining a roster of members or other 

relevant information should write or contact 

Michele A. Lloyd-Puryear, M.D., Ph.D., 

Maternal and Child Health Bureau, Health 

Resources and Services Administration, 

Room 18A–19, Parklawn Building, 5600 

Fishers Lane, Rockville, Maryland 20857, 

Telephone (301) 443–1080. Information on 

the Advisory Committee is available at

http://mchb.hrsa.gov/programs/genetics/

committee.

Dated: December 8, 2004. 

Tina M. Cheatham, 

Director, Division of Policy Review and 

Coordination.

[FR Doc. 04–27388 Filed 12–14–04; 8:45 am] 

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the meeting of the 

President’s Cancer Panel. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in section 

552b(c)(9)(B), Title 5 U.S.C., as 

amended, because the premature 

disclosure of information and the 

discussions would likely to significantly 

frustrate implementation of 

recommendations.

Name of Committee: President’s Cancer 

Panel. 

Date: January 24–25, 2005. 

Open: January 24, 2005, 8 a.m. to 4 p.m. 

Agenda: Translating Research to Reduce 

Burden of Cancer. 

Place: Memorial Sloan-Kettering Cancer 

Center, 1275 York Avenue, New York, NY 

10021. 

Closed: January 25, 2005, 9 a.m. to 12 p.m. 

Agenda: The Panel will supplement its 

public hearings with discussion of 

prepublication manuscripts on Translating 

Research into Clinical Practice. These 

manuscripts have been provided by their 

authors with the understanding that the 

Panel will not break prepublication embargo 

conditions. 

Place: Memorial Sloan-Kettering Cancer 

Center, 1275 York Avenue, New York, NY 

10021. 

Contact Person: Maureen O. Wilson, PhD, 

Executive Secretary, National Cancer 

Institute, National Institutes of Health, 31 

Center Drive, Building 31, Room 3A18, 

Bethesda, MD 20892, 301/496–1148. 

Any interested person may file written 

comments with the committee by forwarding 

the comments to the Contact Person listed on 

this notice. The comments should include 

the name, address, telephone number and, 

when applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: 

deainfo.nci.nih.gov/advisory/pcp/pcp.htm,

where an agenda and any additional 

information for the meeting will be posed 

when available.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; Cancer Centers Support; 93.398, 

Cancer Research Manpower; 93.399, Cancer 

Control, National Institutes of Health, HHS)

Dated: December 6, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–27407 Filed 12–14–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel